Cytonics

[subscription] Cytonics, a biotech company backed by Stanford and Scripps Research, is developing a potential cure for osteoarthritis. The company's first-generation therapy has treated 10,000+ patients and a more potent second-generation version has cleared Phase 1 clinical trials. The company is raising capital via Regulation CF offering before advancing to Phase 2 studies.. Cytonics